Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $35000.0.

  • ImmunityBio's Other Working Capital Changes fell 540.54% to $35000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 13675.71%. This contributed to the annual value of -$5.5 million for FY2024, which is 814.03% up from last year.
  • Latest data reveals that ImmunityBio reported Other Working Capital Changes of $35000.0 as of Q3 2025, which was down 540.54% from $4.0 million recorded in Q2 2025.
  • ImmunityBio's Other Working Capital Changes' 5-year high stood at $13.4 million during Q2 2022, with a 5-year trough of -$9.7 million in Q1 2023.
  • Over the past 5 years, ImmunityBio's median Other Working Capital Changes value was $37000.0 (recorded in 2024), while the average stood at $275736.8.
  • As far as peak fluctuations go, ImmunityBio's Other Working Capital Changes plummeted by 102717.7% in 2023, and later surged by 1132857.14% in 2025.
  • ImmunityBio's Other Working Capital Changes (Quarter) stood at -$517000.0 in 2021, then skyrocketed by 513.35% to $2.1 million in 2022, then surged by 64.01% to $3.5 million in 2023, then plummeted by 260.31% to -$5.6 million in 2024, then surged by 100.62% to $35000.0 in 2025.
  • Its Other Working Capital Changes stands at $35000.0 for Q3 2025, versus $4.0 million for Q2 2025 and $242000.0 for Q1 2025.